

Ethics, Risk and Compliance

Increasing Transparency - Transfers of Value to Healthcare Professionals and Organisations

Novartis collaborates with Healthcare Professionals and Healthcare Organisations to advance patient care and is committed to openly communicating transfers of value related to these relationships.

Increasing Transparency, what you should know

Collaborative working between healthcare professionals and pharmaceutical companies has long been a driver for advancements in patient care and innovative medicine.

What?

The type of collaborations include:

- Clinical trials and research
- Grants
- Patient education and awareness initiatives
- Attendance at scientific congresses, educational meetings, advisory boards
- Training

Both parties regularly collaborate during early scientific research, clinical trials and medical education in the interest of delivering and advancing high quality patient care.

Who?

This relates to all healthcare professionals (e.g. clinicians, GPs, nurses) and their organisations (e.g. hospitals).

IPHA (Irish Pharmaceutical Healthcare Association) makes public details of certain transfers of value (i.e. payments/benefits in kind) made to healthcare professionals and their organisations.

Novartis Ireland has a strong commitment to ethical and transparent collaboration with healthcare professionals. In light of this commitment, Novartis will now disclose transfers of value on the legal basis of legitimate interest, which means that Novartis will no longer seek consent of healthcare professionals to include their data on the Transfer of Value database. You can learn more from this video and our [privacy notice](#).

Novartis fully supports this Europe-wide initiative, led by the European Federation of Pharmaceutical Industries and Associations (EFPIA) and IPHA.

For more information, please go to www.transferofvalue.ie, [The EFPIA Code](#) or <https://www.novartis.com/esg/reporting/transparency-and-disclosure/paym...>;

Collaboration

At Novartis Ireland, we believe that innovation can have a significant impact on medicine, science and humankind. We are committed to listening, and engaging in trusting and mutually successful collaborative partnerships. We are constantly looking for partners to advise us, and who want to share the journey with us. In Ireland, we greatly appreciate the collaboration of our pharma Industry Council.

We believe the best innovation comes from the practice of shoulder-to-shoulder, curious and inspired and collaboration.

This is summarised in the [Industry Council Charter \(PDF 30 KB\)](#).

The Industry Council is composed of the following people:

- Tony O'Brien (Business Post Columnist, Chartered Director) (Chair):
- Eunan Friel (Managing Director of RCSI Healthcare Management)
- Clare Harney (Director for Digital Health Transformation at HealthTech Ireland)
- Prof Mary Horgan (Infectious Disease Specialist, President of RCPI)
- Eilish McAuliffe (Professor of Health Systems, UCD)
- Frank O' Donnell (Head of Public Sector and Health at Microsoft)
- Prof Pat O'Mahony (Strategy Consultant, Chair HIQA, IMVO and Muir PT)
- Alex White (Senior Counsel, Accredited Mediator)
- Chris White (Group CEO of NCBI)

Source URL: <https://www.novartis.com/ie-en/esg/ethics-risk-and-compliance>

List of links present in page

- <https://www.novartis.com/ie-en/ie-en/esg/ethics-risk-and-compliance>
- <https://www.novartis.com/ie-en/ie-en/general-privacy-notice-business-partners>
- <http://www.transferofvalue.ie>
- <https://efpia.eu/relationships-code/the-efpia-code/>
- <https://www.novartis.com/esg/reporting/transparency-and-disclosure/payments-healthcare-professionals sp>
- https://www.novartis.com/ie-en/ie-en/sites/novartis_ie/files/novartis-industry-council-charter.pdf